Bezafibrate in skeletal muscle fatty acid oxidation disorders: A randomized clinical trial∅RNGREEN, Mette Cathrine; MADSEN, Karen Lindhardt; PREISLER, Nicolai et al.Neurology. 2014, Vol 82, Num 7, pp 607-613, issn 0028-3878, 7 p.Article

Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatographyMASNATTA, L. D; CUNIBERTI, L. A; REY, R. H et al.Journal of chromatography. Biomedical applications. 1996, Vol 687, Num 2, pp 437-442, issn 0378-4347Article

Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia : An Extended Follow-Up of the BIP TrialGOLDENBERG, Ilan; BENDERLY, Michal; GOLDBOURT, Uri et al.Journal of the American College of Cardiology. 2008, Vol 51, Num 4, pp 459-465, issn 0735-1097, 7 p.Article

Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cellsBINSACK, R; STEGMEIER, K; DÖRGE, L et al.European journal of clinical investigation. 1998, Vol 28, Num 2, pp 151-163, issn 0014-2972Article

Bezafibrate administration improves behavioral deficits and tau pathology in P301S miceDUMONT, Magali; STACK, Cliona; CHAN, Robin B et al.Human molecular genetics (Print). 2012, Vol 21, Num 23, pp 5091-5105, issn 0964-6906, 15 p.Article

Physicochemical changes in HDL₃ after bezafibrate treatment : Influence on free cholesterol efflux from human fibroblastsLA VILLE, A. E; SOLA, R; MOTTA, C et al.Cardiovascular drugs and therapy. 1997, Vol 11, Num 5, pp 653-658, issn 0920-3206Article

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover studyNOGUCHI, Tohru; KOBAYASHI, Junji; TAKATA, Mutsuko et al.Atherosclerosis. 2011, Vol 217, Num 1, pp 165-170, issn 0021-9150, 6 p.Article

Exposure to human pharmaceuticals Carbamazepine, Ibuprofen and Bezafibrate causes molecular effects in Dreissena polymorphaCONTARDO-JARA, Valeska; LORENZ, Claudia; PFLUGMACHER, Stephan et al.Aquatic toxicology. 2011, Vol 105, Num 3-4, pp 428-437, issn 0166-445X, 10 p.Article

Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemiaAYAORI, Makoto; MOMIYAMA, Yukihiko; TANIGUCHI, Hiroaki et al.Atherosclerosis. 2008, Vol 196, Num 1, pp 425-433, issn 0021-9150, 9 p.Article

Effects of Amlodipine, Captopril, and Bezafibrate on Oxidative Milieu in Rats with Fatty LiverACKERMAN, Zvi; ORON-HERMAN, Mor; ROSENTHAL, Talma et al.Digestive diseases and sciences. 2008, Vol 53, Num 3, pp 777-784, issn 0163-2116, 8 p.Article

Effects of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc, Mytilus galloprovincialisCANESI, L; LORUSSO, L. C; CIACCI, C et al.Chemosphere (Oxford). 2007, Vol 69, Num 6, pp 994-1002, issn 0045-6535, 9 p.Article

Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemiaSAITO, Yasushi; YAMADA, Nobuhiro; SHIRAI, Kohji et al.Atherosclerosis. 2007, Vol 194, Num 2, pp 505-511, issn 0021-9150, 7 p.Article

Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapyHANEFELD, Christoph; BULUT-STREICH, Nadine; BULUT, Daniel et al.Cardiovascular drugs and therapy. 2005, Vol 19, Num 2, pp 153-155, issn 0920-3206, 3 p.Article

Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the ratKAMISAKO, Toshinori; OGAWA, Hiroshi.Journal of gastroenterology and hepatology. 2004, Vol 19, Num 8, pp 879-883, issn 0815-9319, 5 p.Article

Effect of atorvastation and benzafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemiaMORIARTY, Patrick M; BACKES, James M.Atherosclerosis. 2003, Vol 166, Num 1, issn 0021-9150, p. 201Article

Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia : Effect of the lipid-lowering agents, atorvastatin and bezafibrateCANUDAS, J; CENARRO, A; CIVEIRA, F et al.Metabolism, clinical and experimental. 2001, Vol 50, Num 4, pp 447-450, issn 0026-0495Article

Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapyMCCARTY, M. F.Medical hypotheses. 2001, Vol 57, Num 2, pp 216-220, issn 0306-9877Article

Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cellsRODRIGUEZ, Cristina; CABRERO, Agatha; ROGLANS, Nuria et al.Biochemical pharmacology. 2001, Vol 61, Num 3, pp 357-364, issn 0006-2952Article

Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapyJONKERS, I. J. A. M; DE MAN, F. H. A. F; VAN TILBURG, N. H et al.Blood coagulation & fibrinolysis. 2001, Vol 12, Num 8, pp 705-712, issn 0957-5235Article

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitusRUSTEMEIJER, C; SCHOUTEN, J. A; VOERMAN, H. J et al.Diabetes/metabolism research and reviews (Print). 2000, Vol 16, Num 2, pp 82-87, issn 1520-7552Article

New strong fibrates with piperidine moietyKOMOTO, Teruo; HIROTA, Hiroyuki; OTSUKA, Mari et al.Chemical and pharmaceutical bulletin. 2000, Vol 48, Num 12, pp 1978-1985, issn 0009-2363Article

Pharmacodynamic effects of bezafibrate and niacin combination : Implications of the mode of administrationLOMNICKY, Yossef; HAIMOV, Tali; LURIA, Myron H et al.Journal of pharmaceutical sciences. 2000, Vol 89, Num 8, pp 1046-1053, issn 0022-3549Article

A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrateCROOK, M. A; LYNAS, J; WRAY, R et al.Journal of clinical pathology. 2000, Vol 53, Num 10, pp 796-797, issn 0021-9746Article

Activated platelets in patients with severe hypertriglyceridemia : effects of triglyceride-lowering therapyDE MAN, Frits H; NIEUWLAND, Rienk; VAN DER LAARSE, Arnoud et al.Atherosclerosis. 2000, Vol 152, Num 2, pp 407-414, issn 0021-9150Article

Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia : efficacy and safetyGAVISH, D; LEIBOVITZ, E; SHAPIRA, I et al.Journal of internal medicine. 2000, Vol 247, Num 5, pp 563-569, issn 0954-6820Article